Pizer ($PFE (+0,23 %) ) shared breakthrough Phase 3 CREST trial results for sasanlimab, an anti-PD-1 monoclonal antibody, combined with BCG therapy for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
🔑 Key Highlights:
✅ Primary Goal Achieved: Significant boost in event-free survival (EFS) vs. BCG alone.
🏆 First Advance in 30+ Years: Could be the first PD-1 inhibitor approved for this tough-to-treat cancer.
🌍 Global Impact: Targets ~100K new cases/year, with 40-50% facing recurrence.
🤝 Safety Check: Aligned with known safety profiles of PD-1 inhibitors and BCG.
Pfizer plans to submit these pivotal results for regulatory approval soon, aiming to redefine treatment options for patients with limited bladder-sparing choices.
💼 This progress strengthens Pfizer’s oncology pipeline and reinforces its position in innovative cancer care.
💬 Let's Chat !
What are your thoughts on Pfizer’s latest advancements in bladder cancer treatment? Could this mark a new era for non-muscle invasive bladder cancer therapies? Share your insights in the comments, like this post, and pass it along to your network ! 👍🏻
